INmune Bio, Inc. Reports Combination Therapy with INB03™ Overcomes Resistance to Trastuzumab-Deruxtecan in MUC4 expressing HER2+ Breast Cancer

(marketscreener.com) Neutralizing soluble TNF with INB03™ overcomes resistance to trastuzumab-deruxtecan in MUC4 expressing HER2+breast cancer. Combination therapy of INB03™ and trastuzumab-deruxtecan presented at the 45th annual San Antonio Breast Cancer Symposium today Boca Raton, Florida, Dec. 06, 2022 --   INmune Bio, Inc. ...https://www.marketscreener.com/quote/stock/INMUNE-BIO-INC-54264494/news/INmune-Bio-Inc-Reports-Combination-Therapy-with-INB03-trade-Overcomes-Resistance-to-Trastuzumab-D-42489585/?utm_medium=RSS&utm_content=20221206